Skip to content
RDL Network logo
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis — Takeshi Hatanaka (2025) | RDL Network